haematologica

Beyond somatic mutations: the role of next generation sequencing in identifying germline predisposition in patients with acute myeloid leukemia

by Sanam Loghavi and Farhad Ravandi

Beyond somatic mutations: the role of next generation sequencing in identifying germline predisposition in patients with acute myeloid leukemia

Sanam Loghavi[1], and Farhad Ravandi[2]

Departments of [1]Hematopathology and [2]Leukemia, MD Anderson Cancer Center, Houston, TX, USA

Word count: 796

Corresponding Authors:

Sanam Loghavi, MD

Department of Hematopathology

MD Anderson Cancer Center, Houston, TX, USA

sloghavi@mdanderson.org

Farhad Ravandi, MD

Department of Leukemia

MD Anderson Cancer Center, Houston, TX, USA

fravandi@mdanderson.org

In their study published in this issue of the journal, Ahn et al.[1] highlight the critical role of serial next-generation sequencing (NGS) in detecting germline predisposition in acute myeloid leukemia (AML). By analyzing paired samples from 343 patients with AML from 17 institutions, at diagnosis and at complete remission (CR), the authors identified germline mutations in 5.5% of patients, with DDX41 being the most commonly mutated gene. This work highlights the potential of NGS in identifying inherited pathogenic genetic variants, with significant implications for clinical management, genetic counseling, and therapeutic decision-making in patients with AML. (**Figure 1)**

AML is a heterogeneous hematopoietic stem cell neoplasm, commonly driven by a complex interplay of somatic genetic alterations; however, a subset of patients carry germline pathogenic mutations that predispose them to myeloid neoplasms.[2,3] While somatic mutations have long guided risk stratification and treatment, the recognition of germline predisposition has reshaped our understanding of AML etiology and prognosis[4]. These germline variants not only increase the risk of AML but also influence treatment outcomes, particularly in the context of allogeneic hematopoietic stem cell transplantation (HSCT)[4,5]. In this study, Ahn et al. demonstrate that serial NGS, leveraging paired diagnostic and CR samples, can reliably distinguish germline from somatic variants, a distinction critical for the management of these patients.

The study's methodology is robust, targeting 83 genes associated with myeloid malignancies and focusing on 15 genes linked to germline predisposition[6]. By employing a variant allele frequency (VAF) threshold of 40%-60% to flag potential germline mutations and their persistence in CR samples, the authors identified pathogenic germline variant in 5.5% of the study cohort with *DDX41* mutations in 58% among patients with germline variants, followed by *DNAH5*, *CEBPA*, *TP53*, *MPL*, and *GATA2*. The predominance of DDX41 mutations aligns with prior reports linking this variant to familial cases of AML[7,8]. Notably, the study reclassified certain mutations, annotated initially as variants of uncertain significance (VUS) in *DDX41* and *CEBPA,* as causal germline mutations when accompanied by somatic mutations, highlighting the nuanced interpretation required in genetic analysis. **Table 1** summarizes key germline mutations identified in the study, emphasizing their prevalence and clinical significance.

Clinically, patients with germline mutations exhibited distinct features, including lower bone marrow blast percentages and hypoplastic marrow, suggesting a unique disease phenotype. Although these patients showed a trend toward reduced overall survival (OS), multivariate analysis revealed that age, ELN risk, and HSCT were stronger

prognostic determinants. Importantly, germline mutation status did not adversely affect post-HSCT outcomes, affirming the role of HSCT as a therapeutic option for this group of patients. This finding is particularly reassuring, as pathogenic germline variants in genes such as *TP53* have historically raised concerns about treatment-related toxicities [9].

The study's implications extend beyond diagnostics to genetic counseling and donor selection for HSCT. Identifying germline mutations in AML patients enables cascade testing of family members, facilitating early intervention and informed donor choices[6]. For instance, confirming a germline *DDX41* mutation in a patient should prompt screening of related donors to avoid selecting a donor with the same pathogenic mutation when possible. However, in some cases, the only possible donor for a patient

might be a relative who also carries the same pathogenic germline mutation. In such situations, the risks and benefits of selecting that donor must be carefully weighed, and the final decision should be made on a case-by-case basis, taking into account the risk-benefit balance.

Moreover, the persistence of germline variants during CR, as detected by serial NGS, underscores the need for ongoing monitoring to guide therapeutic adjustments, as these germline variants should not be interpreted as persistence of AML-associated mutations and molecular evidence of measurable residual disease (MRD).[6,10]

Despite its strengths, the study has limitations. The targeted NGS panel, while focused, may miss rare germline variants outside the 15 prioritized genes. Whole-exome or whole-genome sequencing could enhance detection rates. Additionally, the absence of functional studies or family genetic assessments limits insights into variant pathogenicity. Selection bias, stemming from the inclusion of only patients achieving CR, may also skew prevalence estimates.

Ahn et al.'s findings further highlight the need to integrate serial NGS into routine AML care. By identifying germline predisposition, clinicians can tailor risk stratification, refine treatment strategies, and provide more effective genetic counseling. The study also calls for broader adoption of NGS panels in clinical practice, supported by standardized guidelines for variant interpretation.[11] We are optimistic that broader use of NGS in clinical care for surveillance of patients with AML will be more routinely adopted as NGS technology evolves, becoming more cost-effective and more readily accessible.

In conclusion, Ahn et al.'s study[1] represents an important step toward precision oncology in AML. By harnessing serial NGS, the authors reveal the prevalence and clinical significance of germline predisposition, paving the way for personalized treatment and improved outcomes in patients with AML.

References

1.   Ahn J-S, Park JH, Lee C, et al. Serial next-generation sequencing for detecting germline predisposition in acute myeloid leukemia. Haematologica. xxx.

2.   Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345-1377.

3.   Godley LA, DiNardo CD, Bolton K. Germline Predisposition in Hematologic Malignancies: Testing, Management, and Implications. Am Soc Clin Oncol Educ Book. 2024;44(3):e432218.

4.   Speight B, Hanson H, Turnbull C, et al. Germline predisposition to haematological malignances: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group. Br J Haematol. 2023;201(1):25-34.

5.   Yang F, Long N, Anekpuritanang T, et al. Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML. Blood. 2022;139(8):1208-1221.

6.   Duncavage EJ, Bagg A, Hasserjian RP, et al. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 2022;140(21):2228-2247.

7.   Bataller A, Loghavi S, Gerstein Y, et al. Characteristics and clinical outcomes of patients with myeloid malignances and DDX41 variants. Am J Hematol. 2023;98(11):1780-1790.

8.   Choi E-J, Cho Y-U, Hur E-H, et al. Unique ethnic features of mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia. Haematologica. 2022;107(2):510-518.

9.   Swaminathan M, Bannon SA, Routbort M, et al. Hematologic malignances and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud. 2019;5(1):a003210.

10.   Kim T, Moon JH, Ahn J-S, et al. Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse. Blood. 2018;132(15):1604-1613.

11.   Li MM, Datto M, Duncavage EJ, et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19(1):4-23.

**Table 1. Key Germline Mutations in AML Identified by Serial NGS in This Study.**

Gene	Prevalence (% of Germline Cases)	Common Variants	Clinical Implications
DDX41	58%	p.A500fs, p.A550fs	Associated with familial AML, older age at onset
DNAH5	16%	p.R1883*, p.S914*	Rare, linked to hypoplastic marrow
CEBPA	11%	Biallelic mutations	Often accompanied by somatic mutations
TP53	11%	p.R248Q, p.G44S	Potential for treatment-related toxicities
MPL	5%	p.R357*	Rare, pathogenic
GATA2	5%	p.G200fs	Linked to myeloid malignancies

Figure Legend

Figure 1. Serial NGS identifies germline predisposition in AML: clinical therapeutic implications. Schematic representation of the workflow of serial next-generation sequencing utilized in the study by Ahn et al. to identify germline predisposition to myeloid neoplasms. The study findings, clinical implications, and limitations are summarized in this schematic. (Created in BioRender. Loghavi, S. (2025) https://BioRender.com/0s30l8r)

Diagnosis sample- NGS

CR Sample -NGS

Germline Mutation Detection

- 343 AML patients, 17 institutions
- Targeted NGS: 83 genes, 15 linked to germline predisposition
- Variant Allele Frequency (VAF): 40%–60% in CR to identify germline mutations

5.5% germline mutations

Prevalence of germline mutations

100%

50%

0

DDX41 *DNAH5* *CEBPA* *TP53* *MPL* *GATA2*

- 5.5% of AML patients had germline mutations
- *DDX41* most common (58%), followed by *DNAH5, CEBPA, TP53, MPL, GATA2*
- Distinct phenotype: lower bone marrow blasts, hypoplastic marrow
- No impact on post-HSCT outcomes

Implications

- Distinguishes germline vs. somatic variants
- Guides risk stratification & treatment
- Informs genetic counseling & donor selection for HSCT

Limitations

- Targeted panel may miss rare variants
- Lacks functional studies/family assessments
- Possible selection bias (CR patients)

Future: Whole-exome/genome sequencing, standardized NGS guidelines